• Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis 

      Holmøy, Trygve; Fevang, Børre; Olsen, David Benee; Spigset, Olav; Bø, Lars (Peer reviewed; Journal article, 2019-08-12)
      Objective: Sporadic fatal adverse events have been reported during treatment of multiple sclerosis with alemtuzumab. To provide a systematic overview, we searched the centralized European Medicines Agency database of ...
    • Dietary Vitamin D3 Supplements Reduce Demyelination in the Cuprizone Model 

      Wergeland, Stig; Torkildsen, Øivind; Myhr, Kjell-Morten; Aksnes, Lage; Mørk, Sverre; Bø, Lars (Peer reviewed; Journal article, 2011-10-20)
      Vitamin D is emerging as a probably important environmental risk factor in multiple sclerosis, affecting both susceptibility and disease progression. It is not known to what extent this effect is due to a modulation of ...
    • Disease-modifying treatments for multiple sclerosis – a review of approved medications 

      Torkildsen, Øivind; Myhr, Kjell-Morten; Bø, Lars (Peer reviewed; Journal article, 2015-11-13)
      Background and purpose: There is still no curative treatment for multiple sclerosis (MS), but during the last 20 years eight different disease-modifying compounds have been approved for relapsing remitting MS (RRMS). ...
    • The economic impact of multiple sclerosis to the patients and their families in Norway 

      Svendsen, Bjørn; Grytten, Nina; Bø, Lars; Aarseth, Hallvard Gilje; Smedal, Tori; Myhr, Kjell-Morten (Peer reviewed; Journal article, 2018-12)
      Background: Multiple sclerosis (MS) imposes high economic costs on society, but the patients and their families have to bear some of these costs. Objective: We aimed to estimate the magnitude of these economic costs in ...
    • Employment among patients with multiple sclerosis - A population study 

      Lunde, Hanne Marie; Telstad, Wenche; Torkildsen, Nina Agnethe Grytten; Kyte, Lars; Aarseth, Jan; Myhr, Kjell-Morten; Bø, Lars (Peer reviewed; Journal article, 2014-07-23)
    • Fingolimod does not enhance cerebellar remyelination in the cuprizone model 

      Alme, Maria Nordheim; Nystad, Agnes Elisabeth; Bø, Lars; Myhr, Kjell-Morten; Vedeler, Christian A.; Wergeland, Stig; Torkildsen, Øivind (Journal article, 2015-08)
      Fingolimod (FTY720) is approved for treatment of relapsing–remitting multiple sclerosis. In vitro studies have found that fingolimod stimulates remyelination in cerebellar slices, but in vivo animal studies have not detected ...
    • Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model 

      Fjær, Sveinung; Bø, Lars; Myhr, Kjell-Morten; Torkildsen, Øivind; Wergeland, Stig (Peer reviewed; Journal article, 2015-03-02)
      Magnetization transfer ratio (MTR) is a magnetic resonance imaging (MRI) method which may detect demyelination not detected by conventional MRI in the central nervous system of patients with multiple sclerosis (MS). A ...
    • Poor Sleep in Patients with Multiple Sclerosis 

      Lunde, Hanne Marie Bøe; Aae, Tommy F.; Indrevåg, William; Aarseth, Jan Harald; Bjorvatn, Bjørn; Myhr, Kjell-Morten; Bø, Lars (Peer reviewed; Journal article, 2012-11-14)
      Background: Poor sleep is a frequent symptom in patients with multiple sclerosis (MS). Sleep may be influenced by MS-related symptoms and adverse effects from immunotherapy and symptomatic medications. We aimed to study ...
    • Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study 

      Torgauten, Hilde Marie; Myhr, Kjell-Morten; Wergeland, Stig; Bø, Lars; Aarseth, Jan Harald; Torkildsen, Øivind (Journal article; Peer reviewed, 2021-01-31)
      Background Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS). More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo patients and patients in early therapy ...
    • Survival and cause of death in multiple sclerosis: A 60-year longitudinal population study 

      Lunde, Hanne Marie; Assmus, Jörg; Myhr, Kjell-Morten; Bø, Lars; Grytten, Nina (Peer reviewed; Journal article, 2017)
      Objective: Survival and causes of death (COD) in multiple sclerosis (MS) provide ultimate endpoints. We aimed to investigate survival and COD in a 60-year population-based MS cohort compared with the general population. ...